Embla Medical hf
Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and … Read more
Embla Medical hf (EMBLA) - Total Liabilities
Latest total liabilities as of December 2025: Dkr848.71 Million DKK
Based on the latest financial reports, Embla Medical hf (EMBLA) has total liabilities worth Dkr848.71 Million DKK as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Embla Medical hf - Total Liabilities Trend (2020–2025)
This chart illustrates how Embla Medical hf's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Embla Medical hf Competitors by Total Liabilities
The table below lists competitors of Embla Medical hf ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sinopec Shanghai Petrochemical Company Limited
PINK:SPTJF
|
USA | $16.21 Billion |
|
Jiangsu Yueda Investment Co Ltd
SHG:600805
|
China | CN¥5.07 Billion |
|
Beingmate Baby & Child Food Co Ltd
SHE:002570
|
China | CN¥2.26 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥2.54 Billion |
|
Long Young Electronic (Kunshan) Co. Ltd. A
SHE:301389
|
China | CN¥94.31 Million |
|
Jiangyin Haida Rubber and Plastic Co Ltd Class A
SHE:300320
|
China | CN¥1.22 Billion |
|
Diös Fastigheter AB (publ)
F:D1F
|
Germany | €21.18 Billion |
|
Pantoro Limited
F:RKN
|
Germany | €183.49 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Embla Medical hf's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Embla Medical hf's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Embla Medical hf (2020–2025)
The table below shows the annual total liabilities of Embla Medical hf from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr848.71 Million | +11.93% |
| 2024-12-31 | Dkr758.27 Million | +11.40% |
| 2023-12-31 | Dkr680.68 Million | -1.33% |
| 2022-12-31 | Dkr689.85 Million | +11.21% |
| 2021-12-31 | Dkr620.32 Million | -2.64% |
| 2020-12-31 | Dkr637.14 Million | -- |